ARTICLE | Clinical News
Janssen completes Phase III studies of IM Risperdal
February 20, 2001 8:00 AM UTC
ALKS said that partner Janssen Pharmaceutica (Beerse, Belgium), a subsidiary of Johnson & Johnson (JNJ), completed two Phase III trials of its Risperdal risperidone sustained release depot intramuscul...